Trial Profile

An Open-label, Interventional, Multicenter, Randomized, Phase 2 Study of Fulvestrant With or Without Samuraciclib in Participants With Metastatic or Locally Advanced Hormone Receptor (HR) Positive and Human Epidermal Growth Factor Receptor (HER)2-Negative Breast Cancer (BC)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 26 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fulvestrant (Primary) ; Samuraciclib (Primary)
Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer
Focus Therapeutic Use
Acronyms SUMIT-BC
Sponsors Carrick Therapeutics

21 Feb 2025 Planned End Date changed from 16 Jun 2025 to 31 Dec 2025.
21 Feb 2025 Planned primary completion date changed from 30 Dec 2024 to 30 Jun 2025.
14 Oct 2024 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com